{"id":3471,"date":"2022-06-10T12:24:36","date_gmt":"2022-06-10T16:24:36","guid":{"rendered":"https:\/\/albanyentandallergy.fm1.dev\/?p=3471"},"modified":"2022-06-10T12:24:38","modified_gmt":"2022-06-10T16:24:38","slug":"dr-gavin-setzen-and-dr-nora-perkins-help-lead-breakthrough-clinical-research-to-restore-hearing-loss","status":"publish","type":"post","link":"https:\/\/albanyentandallergy.com\/dr-gavin-setzen-and-dr-nora-perkins-help-lead-breakthrough-clinical-research-to-restore-hearing-loss\/","title":{"rendered":"Dr. Gavin Setzen and Dr. Nora Perkins Help Lead Breakthrough Clinical Research to Restore Hearing Loss"},"content":{"rendered":"
Albany, NY \u2013 (June 9th, 2022) The mission at Albany ENT & Allergy Services (AENT), the preeminent private otolaryngology practice in the Capital Region, is to offer superior ear, nose, throat, allergy and sleep care to each one of its Capital Region patients. But AENT\u2019s commitment to its community also includes participation in the development of new treatments and medical advancements in all aspects of Otolaryngology.<\/p>\n\n\n\n
Consistent with that, AENT today announced it is participating in a nationwide clinical trial of a novel regenerative medicine candidate that may help restore hearing in patients with sensorineural hearing loss (SNHL). SNHL, which is often caused by exposure to loud sounds, aging, infections, medications that are toxic to the ear or hearing loss that can occur suddenly, is the most common form of hearing loss, affecting more than 41 million Americans.<\/p>\n\n\n\n
AENT is currently recruiting adults with noise-induced and sudden SNHL who may qualify for a clinical trial of FX-322, a drug candidate designed to regenerate sensory cells necessary for healthy hearing. Sponsored by Frequency Therapeutics, the study is placebo-controlled and will evaluate outcomes in speech perception, a key measure of hearing function.<\/p>\n\n\n\n
\u201cWe are delighted to be participating in this potentially game changing research,\u201d stated Dr. Nora Perkins, senior partner at AENT, \u201cWe believe this drug candidate has the potential to help thousands upon thousands of our patients.\u201d Added Dr. Gavin Setzen, AENT\u2019s President, “We encourage anyone, even with the slightest symptoms, to get their hearing checked. Untreated hearing loss can, unfortunately, have a huge impact on a person\u2019s health and quality of life.\u201d<\/p>\n\n\n\n